Background:Osteoarthritis is a slowly progressive disorder associated with a hyaline cartilage loss. Non-steroidal antiinflammatory drugs play a pertinent role in management of osteoarthritis. Objectives: The study was carried out for the comparison of efficacy and tolerability of Aceclofenac and Diclofenac in patients of osteoarthritis of knee joint. Material and Methods: It is a randomised parallel group double blinded study. The study included 60 patients of confirmed osteoarthritis of knee joint, 30 patients were given Aceclofenac and 30 patients were given Diclofenac after food for 8 weeks and the patients were evaluated and compared statistically for pain intensity by VAS Score, Joint tenderness, Swelling, Erythema, Pain on movement, Functional capacity and Overall Assessment on LIKERT Scale. Results: Both the drugs caused marked improvements in the parameters of -Pain intensity, Joint tenderness, Swelling, Erythema, Pain on movement of OA knee joint but there was increased improvement in all the parameters with aceclofenac. Conclusion: Aceclofenac is the NSAID of choice in the osteoarthritis of knee joint as compare to Diclofenac.
12048 Background: Financial toxicity (FT) of cancer is prevalent among older patients in high-income countries, but there is no data about the financial burden faced by older patients in India. This study aimed to explore the FT of cancer among older Indian patients. Methods: This was a cross-sectional observational study conducted in the geriatric oncology clinic of Tata memorial hospital (Mumbai, India). Patients aged 60 years and above with cancer were included. Patients and their relatives were enquired regarding their occupations, monthly income, and source of funding for cancer treatment. The modified Kuppuswamy scale was used for stratification of socio-economic status (SES). The financial burden was evaluated using the Comprehensive Score for Financial Toxicity-Functional Assessment of Chronic Illness Therapy (COST-FACIT) scale. In addition, the Consumer Financial Protection Bureau Financial Well-Being Scale and the 28th question of QORTC QLQ-C30 were used to assess the financial quality of life. Results: Between June 2022 and January 2023, 498 patients were included. The median age was 67 (IQR, 63-72) years, and 360 (72.3%) were male. Common malignancies included gastrointestinal (199, 40.0%), lung (169, 34.0%) and urological (63, 12.7%); 320 (64.4%) had metastatic disease. According to the modified Kuppuswamy scale, most of the participants belonged to upper-lower SES (223, 44.8%), followed by lower-middle (115, 23.1%), upper-middle (97, 19.5%), lower (59,11.8%) and only 4 (0.8%) belonged to upper SES. The source of funding was mostly from family members (264, 53.9%), insurance (72, 14.7%), while 59 patients (12.0%) did not require external support. Sixty-one (12.4%) had to borrow money, twenty-one (4.3%) participants had taken a loan, and 13 (2.6%) had sold their assets for the purposes of treatment. Moderate-severe burden on COST-FACIT was present in 165 (33.1%), whereas 333 (66.9%) experienced no or mild burden. High FT was associated with lower socioeconomic status (OR: 4.69, 95%CI 2.47-8.91, p-value < 0.001), poor financial well-being (OR: 9.35, 95%CI 5.52-16.46, p-value < 0.001) and poor score on Financial quality of life (OR: 5.16, 95%CI 3.39-7.86, p-value < 0.001). Conclusions: In older Indian patients with cancer, there is a high prevalence of financial burden and is associated with poor socioeconomic status, poor financial well-being and poor financial quality of life. More than half the patients depended on their family members to meet the cost of cancer treatment.
Background: Gout, resulting from the precipitation of urate crystals in the tissues and the subsequent inflammatory response, causes an exquisitely painful distal monoarthritis alongwith joint destruction, subcutaneous deposits (tophi), renal calculi. The main culprit is uric Acid, which is a waste product formed due to purine metabolism. Gout Patients either produce excess Uric acid or are unable to excrete Uric acid produced in normal conditions. Uric acid lowering therapy (ULT) has become popular regarding management of gout. Nowadays. 2 drugs which are responsible for decreasing synthesis of Uric acid are Febuxostat and Allopurinol. The purpose of this study is to determine efficacy of Febuxostat and Allopurinol experienced by patients during course of therapy.Methods: It was an open, prospective, observational, non-invasive, parallel and randomised study, conducted at the Outpatient Department of Urology, Rajindra Hospital, Patiala. It had 60 patients of gout, out which, 30 patients were administered Febuxostat and 30 patients were administered Allopurinol. For each patient, history regarding drug intake was taken, along with analysis of Serum Uric acid profile before prescription and during follow up.Results: The mean age selected for study was 47 years for Febuxostat group and 43 years for Allopurinol group. Mean Urate (mg%) in pre-treatment stage of patients of Febuxostat group is about 8.28 whereas for Allopurinol group its about 8.61. Mean urate levels after 4 follow ups (10 days each) were conducted. The mean Urate level at 10, 20, 30, 40 days were conducted at each group which were found to be statistically significant and the results of Febuxostat group was found to be favourable.Conclusions: Febuxostat, (40mg) given at daily dose was found to have higher efficacy than allopurinol, at a dose of 100mg (zyloric) which is the most commonly prescribed dose in order to lower the serum urate level.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.